DAB2 and neoplasm: DAB2 downregulation, which results in suppressing R-Smad/canonical TGF-β signaling, not only correlates with poor prognosis but also fundamentally alters the TGF-β response from a tumor suppressor into a potent promoter of migration, anchorage-independent growth, and in vivo tumor growth.